FGF21 RECEPTOR AGONISTS AND USES THEREOF
The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ßKlotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 a...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GROMADA, JESPER YANCOPOULOS, GEORGE D MURPHY, ANDREW J BUCKLER, DAVID R KANG, KIHWA |
| description | The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ßKlotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.
La présente invention concerne des agonistes de la signalisation de FGF21. En particulier, la présente invention concerne des agonistes du récepteur de FGF21 (FGF21R) qui peuvent lier simultanément ßKlotho (KLB) et/ou FGFR1c pour imiter l'activité de signalisation de FGF21. La présente invention concerne également des anticorps anti-FGF21 et anti-KLB/FGFR1c et leurs fragments de liaison aux antigènes. L'invention concerne également des procédés de traitement de divers troubles métaboliques par l'administration des agonistes de FGF21R et/ou des anticorps anti-FGF21 à un sujet qui en a besoin. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA2943355C</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA2943355C</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA2943355C3</originalsourceid><addsrcrecordid>eNrjZNBwc3czMlQIcnV2DQjxD1JwdPf38wwOCVZw9HNRCA12DVYI8XANcvV342FgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8c6ORpYmxsamps7GhFUAAF4SIvU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FGF21 RECEPTOR AGONISTS AND USES THEREOF</title><source>esp@cenet</source><creator>GROMADA, JESPER ; YANCOPOULOS, GEORGE D ; MURPHY, ANDREW J ; BUCKLER, DAVID R ; KANG, KIHWA</creator><creatorcontrib>GROMADA, JESPER ; YANCOPOULOS, GEORGE D ; MURPHY, ANDREW J ; BUCKLER, DAVID R ; KANG, KIHWA</creatorcontrib><description>The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ßKlotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.
La présente invention concerne des agonistes de la signalisation de FGF21. En particulier, la présente invention concerne des agonistes du récepteur de FGF21 (FGF21R) qui peuvent lier simultanément ßKlotho (KLB) et/ou FGFR1c pour imiter l'activité de signalisation de FGF21. La présente invention concerne également des anticorps anti-FGF21 et anti-KLB/FGFR1c et leurs fragments de liaison aux antigènes. L'invention concerne également des procédés de traitement de divers troubles métaboliques par l'administration des agonistes de FGF21R et/ou des anticorps anti-FGF21 à un sujet qui en a besoin.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230905&DB=EPODOC&CC=CA&NR=2943355C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230905&DB=EPODOC&CC=CA&NR=2943355C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GROMADA, JESPER</creatorcontrib><creatorcontrib>YANCOPOULOS, GEORGE D</creatorcontrib><creatorcontrib>MURPHY, ANDREW J</creatorcontrib><creatorcontrib>BUCKLER, DAVID R</creatorcontrib><creatorcontrib>KANG, KIHWA</creatorcontrib><title>FGF21 RECEPTOR AGONISTS AND USES THEREOF</title><description>The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ßKlotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.
La présente invention concerne des agonistes de la signalisation de FGF21. En particulier, la présente invention concerne des agonistes du récepteur de FGF21 (FGF21R) qui peuvent lier simultanément ßKlotho (KLB) et/ou FGFR1c pour imiter l'activité de signalisation de FGF21. La présente invention concerne également des anticorps anti-FGF21 et anti-KLB/FGFR1c et leurs fragments de liaison aux antigènes. L'invention concerne également des procédés de traitement de divers troubles métaboliques par l'administration des agonistes de FGF21R et/ou des anticorps anti-FGF21 à un sujet qui en a besoin.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNBwc3czMlQIcnV2DQjxD1JwdPf38wwOCVZw9HNRCA12DVYI8XANcvV342FgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8c6ORpYmxsamps7GhFUAAF4SIvU</recordid><startdate>20230905</startdate><enddate>20230905</enddate><creator>GROMADA, JESPER</creator><creator>YANCOPOULOS, GEORGE D</creator><creator>MURPHY, ANDREW J</creator><creator>BUCKLER, DAVID R</creator><creator>KANG, KIHWA</creator><scope>EVB</scope></search><sort><creationdate>20230905</creationdate><title>FGF21 RECEPTOR AGONISTS AND USES THEREOF</title><author>GROMADA, JESPER ; YANCOPOULOS, GEORGE D ; MURPHY, ANDREW J ; BUCKLER, DAVID R ; KANG, KIHWA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA2943355C3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>GROMADA, JESPER</creatorcontrib><creatorcontrib>YANCOPOULOS, GEORGE D</creatorcontrib><creatorcontrib>MURPHY, ANDREW J</creatorcontrib><creatorcontrib>BUCKLER, DAVID R</creatorcontrib><creatorcontrib>KANG, KIHWA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GROMADA, JESPER</au><au>YANCOPOULOS, GEORGE D</au><au>MURPHY, ANDREW J</au><au>BUCKLER, DAVID R</au><au>KANG, KIHWA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FGF21 RECEPTOR AGONISTS AND USES THEREOF</title><date>2023-09-05</date><risdate>2023</risdate><abstract>The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ßKlotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.
La présente invention concerne des agonistes de la signalisation de FGF21. En particulier, la présente invention concerne des agonistes du récepteur de FGF21 (FGF21R) qui peuvent lier simultanément ßKlotho (KLB) et/ou FGFR1c pour imiter l'activité de signalisation de FGF21. La présente invention concerne également des anticorps anti-FGF21 et anti-KLB/FGFR1c et leurs fragments de liaison aux antigènes. L'invention concerne également des procédés de traitement de divers troubles métaboliques par l'administration des agonistes de FGF21R et/ou des anticorps anti-FGF21 à un sujet qui en a besoin.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA2943355C |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | FGF21 RECEPTOR AGONISTS AND USES THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T02%3A35%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GROMADA,%20JESPER&rft.date=2023-09-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA2943355C%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |